494 results on '"Stern, David F"'
Search Results
2. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis
3. ErbB2 Is Required for Ductal Morphogenesis of the Mammary Gland
4. Supplementary Table 8 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
5. Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
6. Supplementary Figure 1 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
7. Data from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
8. Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
9. Data from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
10. Supplementary Table S5 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
11. Data from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
12. Supplementary Table 5 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
13. Data from NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53
14. Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
15. Supplementary Tables 1-3 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
16. Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
17. Supplementary Tables 1-7, 9 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
18. Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
19. Supplementary Table 3 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
20. Supplementary Figure S1 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
21. Supplementary Figure 1 from NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53
22. Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
23. Supplementary Figure 3 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
24. Supplementary Table 1 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
25. Supplementary Table 2 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
26. Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
27. Data from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
28. Supplementary Figure 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
29. Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
30. Supplementary Table 4 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
31. Supplementary figure and table legends from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
32. Supplementary Figure Legends, Table Legends from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
33. Supplementary Table 2 from NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53
34. Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
35. Supplementary Legends for Figure 1 and Tables 1-2 from NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53
36. Supplementary Table 5 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
37. Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
38. Data from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
39. Supplementary Figures 1-7 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
40. Supplementary Table 1 from NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53
41. Supplemental Figure Legends from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
42. Supplementary Table 6 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
43. Supplementary Figure 2 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
44. Supplementary Figure Legends 1-7, Table Legends 1-9 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
45. Supplementary Table 4 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
46. Supplementary Table Legends 1-6, Figure Legend 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
47. Neural and Mammary Gland Defects in ErbB4 Knockout Mice Genetically Rescued from Embryonic Lethality
48. ErbB4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation
49. Supplementary Tables 2-13 from Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
50. Supplementary Tables 1, 2, 4, and 5 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.